Member Info for dickpullar

Response received regarding purpose of interview.

Thank you for reaching out and for your interest in our coverage of Sareum.

 

Regarding your query about the interview with Sareum published on 2 October, the discussion was designed to explore in greater depth the applicability and potential of TYK2 inhibitors in neuroinflammatory conditions such as multiple sclerosis, Parkinson’s, and Alzheimer’s disease. It also highlighted Sareum’s recent initiatives to expand its compound portfolio into these indications. We view this as a potential long-term upside opportunity for the company, extending the relevance of TYK2 beyond its traditional autoimmune focus.

 

That said, while Sareum’s progress and its collaboration with Receptor.AI are promising, these programmes remain at an early stage, with further preclinical validation required. In the near to medium term, we expect the primary value driver for Sareum to remain SDC-1801, with key inflection points likely to arise from the completion of toxicology studies for Phase II and the subsequent initiation of the trial.

 

The interview was aimed at existing shareholders, potential investors, and others with an interest in kinase inhibitors or Sareum. Promotion of our content is handled by our distribution and investor engagement teams, leveraging our extensive email database, professional platforms, news agencies, social media channels, and website to ensure broad dissemination.

 

Yes would like to see an rns confirming all good with 1801 and CNS progressing in tandem

I have emailed Edison to ask them who the interview is targeting and how they plan to further promote it.

I will post the response if I receive one.

Provide positive updates and get sp to £1

Sell 1801 and 737 and give me a £3 special dividend, I can then hold on happily for another 3 years until the rest comes together

I'm hoping the purpose of the interview is to highlight to potential suitors that we have plenty in the locker

Hi Gus, fingers crossed the next update here will be just as spectacular as those views we enjoyed in Arran!

I spent last week in the Isle of Arran, superb weather, beautiful island and the views from the top of Goatfell were spectacular.

I will be looking for a second home in Arran when we hit £3+

If you are to associate sar with my handle then I reckon next week we will reach the tickly bit before we totally erupt with a mid October climax.

Well that’s me all in with another 60000 shares after taking final profits from HEMO

I feel very fortunate to have got in here a few weeks back. I am taking my final slice of profit and sticking it in SAR in preparation for take off

Major investors are holding tight which is good news.

I doubt Roger Meier would be holding £1.5m if he smelt a rat.

Jelly & Ice Cream next month?

Use a sole email address for your lse account then check your spam folder…. You will be astonished at the number of emails and inappropriate content that appears!

No such thing as a free lunch.

The Goose is getting fat

It would be interesting to know tge number of shareholders that we have. I guess it is less than 1000?

Many on this board have holdings of between £25k-£100k, add the directors and major shareholder Rodger Meier then there is not a lot left to go round.

Hemo has been good to me over the last few weeks, I've taken another £5k profit this morning and banked it in here.

If buying back in it is perhaps sensible to exercise warrants now as likely to be large daily fluctuations once news arrives

Yep good buying volume this morning, if no background selling then should shoot up quickly.

The 20-1 lth"s are all in. The 2-1 cautious investors will wait for a reassuring rns....the herd will then follow and we wil hopefully rocket from there.

Thanks for altering us to Hemo rise, managed to get in at 360p on Wedbesday for tidy profit.

Https://markets.ft.com/data/equities/tearsheet/forecasts?s=SAR:LSE

176p by the end of the year and £4+ on t/o is not overly ambitious imho